1

Randall Fitzgerald President and CEO

October 5, 2012

Description of the Company ◦ Advanced Preservation Technologies, LLC (to be formed) is

a new technology development company that intends to either license, design, market, and eventually manufacture its products.

◦ In June of 2009, we obtained an exclusive worldwide license of a preservative that was used in the space program by NASA.

◦ We are also negotiating a license from a major University of a bio-polymer that preserves samples for extended periods of time.

◦ We have already established relationships with reference laboratories and medical supply houses whom have expressed an interest in purchasing said products upon completion of successful research and/or validation.

2

NASA Preservative◦ The specific field of use is to preserve urine, blood, plasma and

serum (largest markets). However, it also preserves saliva, tears, sweat, vaginal fluids, semen, feces, mucous, breast milk, ascites, lymph, pleural effusion, synovial fluid, bone marrow, spino-cerebral fluid, and washings from bodily cavities (e.g., lung washings).

Biopolymer◦ Preserves samples for extended periods of time (12 – 18 months and

longer) at room temperature. It puts the sample in a dormant state and is reconstituted with the addition of a rehydration solution. This system is compatible with many biological samples including proteins, DNA, RNA, receptors, antibodies, antigens, bacteria, mammalian cells, cell surfaces, enzymes and tissues. The polymer is also effective in protecting the biological materials on the surfaces of biosensors. Most importantly, it keeps cells alive (very important attribute). This product has a short path to commercialization as no 510K approvals are required for research applications. We are currently negotiating a sales and distribution arrangement with a major supply house for an exclusive arrangement.

3

Our goal is to initially outsource our production until manufacturing facilities can be arranged. This will give us an almost immediate revenue stream. We have already identified Original Equipment Manufacturers (OEM) to make, bottle, label, and package SUBJECT DATA.

4

Urine◦ We conducted a research program to verify that the preservative preserves clinically

important urine analytes. We focused mainly on Pheochromacytoma patients as it was believed that if we preserved those samples that the others should follow suit.The latest test results gave us 2 days of preservation using the recommended 2ml/100ml of urine. Our desired results are six days. Hence, we need to modify the product as it relates to 24hr urines. We also would like to run test to see how the product performs on routine uA’s and urine cultures. This product has the interest of two very large reference laboratories as well as Becton Dickinson.

Blood, Plasma and Serum◦ Earlier this year, one of the major reference laboratories performed testing on the

blood tubes and the results were very good. In fact, they have stated that if we make these tubes that they would be interested in becoming a customer. This particular company buys 230 million tubes annually. This product has the potential to be a game-changer as blood tubes would no longer require refrigeration and/or to be kept frozen for analysis.

5

Current Applications◦ Our immediate focus will be to go

after the low hanging fruit which would be the applications that has the shortest path to revenue generation and build from there. We believe that the biopolymer provides this opportunity as product is simple to make and no FDA approvals are required for research applications. This will give use a revenue stream while we bring the blood and urine products to practical applications.

◦ We have identified a blood tube manufacturer that can produce our tube while we test and apply for 510K and setup our own manufacturing facilities.

Future Applications◦ The beauty of both our product is

that they have the potential for numerous applications to include forensics, biodegradable packaging, agriculture, oral vaccines and food science. Our advisory board will determine which applications / markets should be given priority.

6

Easy to Prepare and Use - Both solutions are stable and easy to prepare. It is also easy for the average person to use and is capable of coating an aliquot tube.

Inexpensive - This technology is inexpensive to produce. In addition, since samples may be stored at room temperature, the costs which would normally be incurred for the refrigeration and freezing of samples is eliminated.

Refrigeration Not Required - Samples may be collected in remote settings where it was not previously feasible to do so.

Non-toxic and Maintains pH - Preservatives does not alter the pH of a sample. In addition, unlike hydrochloric acid, boric acid, thymol and thymerasol, this preservative is non-toxic.

Biopolymer – Keeps cells alive

7

The global IVD market was valued at $44 billion in the year 2011, growing at a CAGR of 7.8% from 2011 to 2016. The U.S. represented the biggest market for the IVD equipments accounting for a share of 47% of the total IVD market in the year 2011.

Sixty percent (60%) of testing is conducted a hospital laboratories, Thirty-three percent (33%) at commercial labs and the remainder (7%) at Physician labs.

According to Quest, 100% of the urine samples require the use of a preservative and Lab Corp says 85% of their urinalysis requires a preservative. Hence, we used an average number of 93% of urinalysis, urine cultures and molecular diagnostics require the use of a preservative from commercial laboratories. Currently hematology, chemistries and immunoassays do not require a preservative. However, some of those test requires that samples be kept frozen and/or refrigerated. Hence, our approach would be to offer preservations for these applications as well. Storing samples at room temperature could reduce shipping costs as well as save needed space. This gives us a total market of over $8.4 billion dollars not to mention any of the other applications not included like the Bard bags. Hospitals could also be targeted as samples are sometimes inadvertently left unrefrigerated and have to be thrown out and retesting is needed. Our product would alleviate this problem as our samples can be stored on the shelf at room temperature for 6 -7 days..

8

Urinalysis $569 million

Urine

Cultures

$300 million

Hematology $1.8 billion

Molecular

Diagnostics

$2.6 billion

Chemistries $11.8 billion

Immunoassay $10.2 billion

Total Market

$27.4 billion

9

Hospitals $16,445,988,202 60%

Commercial

Labs

$9,045,293,511 33%

$8,412,122,965

Physician Labs $1,918,698,624 7%

Of the $27.4 billion dollar market potential available for our product, our numbers reflect only commercial

laboratories. Hospitals are the largest markets and it is our goal to penetrate these markets. Chemistries,

hematology and Immunoassays do not require the use of a preservative, but some testing require samples to be

frozen. With our product, all samples could be handled the same way and kept unrefrigerated, further streamlining

operations. We have also identified other untapped markets to include urinalysis collection bags (Bard bags) and

hormones.

10

We believe that our numbers are extremely conservative as one major reference laboratory that we

know of buys 20 million urine tubes and 230 million blood tubes annually.

Note: Our projections do not include the bioploymer

Projected Company Financials Year 1 Year 2 Year 3 Year 4 Year 5

Revenue

Urine Tubes $0.400 $0.400 $0.400 $0.400 $0.400

Units Sold (manufactured) 5,000,000 30,000,000 40,000,000 50,000,000 75,000,000

Blood Tubes 0.10 0.10 0.10 0.10 0.10

Units Sold (manufactured) 1 60,000,000 230,000,000 250,000,000 500,000,000

Projected Sales (Blood) $0.00 $ 6,000,000 $ 23,000,000 $ 25,000,000 $ 50,000,000

Projected Sales (Urine) $2,000,000 $12,000,000 $16,000,000 $20,000,000 $30,000,000

Total Sales $2,000,000 $18,000,000 $39,000,000 $45,000,000 $80,000,000

◦ The potential customers are both domestic and foreign. Domestic customers include managed care groups, hospital buying groups, physician groups, independents, catalogues, reference laboratories and medical supply houses. Managed care groups dominate the market. These groups make more that 50% of all purchases of medical devices. The foreign market includes many of the above segments but also include key distributors. For example, distributors are required to penetrate the European, Middle Eastern, African, Central and South American and Japanese

markets. These distributors are being identified.

11

Worldwide Exclusive license

Immediate applications as no FDA approvals required for biopolymer and some urine applications.

Captured interests of the two largest clinical laboratories in the country

Enormous upside potential as product has several applications

Advisory Board with 70 years of experience in the commercialization of medical technologies

12

Biopolymer – No FDA approvals required for research applications.

Urine preservative - According to the FDA, no 510K approvals are required for routine uA’s or 24hr urines. However, 510K approvals are required for urine cultures. (We have gotten mixed messages on this and are currently waiting to hear back from the FDA)

Blood tubes – Anything having to do with blood tubes will require 510K approval.

As there are similar products already on the market, the approval process is about 90 days after you submit your package to the FDA. This is considered a “me too type” application according to the FDA. I am figuring 6 months tops from start to finish.

13

NASA Preservative◦ Currently patients who are required to provide a 24 hour void of urine are required to

take home a container that contains the toxic hydrochloric acid and/or boric acid. This is a liability issue for the laboratories and is of great concern. Our product would alleviate that concern.

◦ The product could also be used to reduce the cost of shipping as current samples have to be rushed to a laboratory. The use of our product would allow for more affordable shipping methods which could literally save millions of dollars.

◦ Samples that are inadvertently left on the shelf for prolonged periods of time have to be discarded. Those samples could still be used if preserved with our product saving time and money as no retesting would be required.

◦ Additionally, our product allows samples to be stored on the shelf, freeing up space in the refrigerator for other applications.

◦ Some blood samples (chemistries and hormones) are required to be kept frozen. Our customers have identified this as a huge problem and our product would alleviate that requirement. We believe that this will be very disruptive to the industry.

14

Biopolymer◦ Various methods for the preservation of biological specimens have evolved over the years. Modern

specimen preparation techniques for microbiology and electron microscopy typically include dehydration and immobilization, both of which are irreversible and often damage the integrity of the specimen.

◦ Dehydration using chemicals or freezing temperatures typically causes structural damage to biological tissues. Chemicals may destroy the overall quality of the specimen, including the particular characteristics of interest to the scientist. Rapid freeze-drying often produces crystalline structures that are destructive to most biological tissues. The result of dehydration is a biological sample that has been significantly altered, beyond repair, from its natural state.

◦ Immobilization of a biological sample within a polymer typically involves curing, using elevated temperatures or ultraviolet radiation, both of which are detrimental to specimen quality. The polymers are resins typically used for sample preparation today form a hard plastic when cured. Once a sample has been cured, the biological material cannot be restored to its isolated state.

◦ Biological specimen preservation techniques are of particular concern in the preparation of biosensors. Biosensors are used in the health and environmental sciences for rapid detection of specific substances. Biosensors are currently used to detect the presence of pesticides, herbicides, and other compounds; to detect the presence of organic compounds such as alcohols, ammonia, and metals; and, to detect the presence of specific bacteria including algae, fungi, and pathogenic organisms such as Escherichia coli (E. coli) and Salmonella. Potential applications for biosensors include sensing pollution and microbial contamination of air and water, clinical diagnosis of medical conditions, fermentation analysis and control, monitoring and analysis of industrial gases and liquids, monitoring of mining conditions and sensing toxic gases.

15

Biopolymer◦ Biosensors often have a very short shelf life because the antibody or other biological receptor

degrades rapidly when exposed to the environment. Like other biological samples, biological receptors need isolation and protection from the environment until ready for use. In field applications especially, a variety of biological receptors may be needed at any time, depending on the conditions.

◦ There is an unsatisfied need in the art for biological samples that can be protected and preserved without the altering or destroying the biological tissue. The demand for safe transport and prolonged storage of biological samples today requires preservation techniques that maintain the integrity and quality of the biological sample. Sensitive biological receptors used in biosensors need to be isolated from the environment, without damaging the receptor, until ready for use. None of the specimen preparation techniques in the art currently meet these needs.

◦ There is also a need in the art for biological samples that can be restored to their isolated or prepared state after immobilization, with minimal damage, for later study or use. The current techniques of dehydration and immobilization are irreversible and destroy sample viability. Restoration is particularly critical for the biological receptors in biosensors, which are especially sensitive. There is a need, therefore, for a preservation technique that is both harmless and reversible.

◦ The above and other needs are met by the present invention which, stated generally, provides a method of using Acacia gum to isolate and preserve biological material without damage to the specimen. The present invention further provides reversible techniques for using Acacia gum that maintains the integrity and viability of biological specimens, even after prolonged storage at room temperature.

16

Randall Fitzgerald will serve as CEO and offers a unique blend and extensive breath of experience relative to this venture. Randall has served in the U.S. Air Force/Georgia National Guard for 22 years and also spearheaded a $2.5 million dollar joint venture that opened a family entertainment center where he served a Co-owner/General Manager. He has already begun to form a working relationship with Quest Diagnostics, NASA, Emory University, Georgia Center of Innovation for Life Sciences, Validation Laboratories and Biosure.

17

Carl Fitzgerald will serve as Vice-President of Corporate Development. He is the current Chairman and CEO of Spotlite Enterprises, Inc. and holds several board seats on multinational companies. He brings a strong concentration in finance, marketing and global development. Additionally, he is also the Ambassador Designee for Liberia.

Deborah Mcneil will serve as CFO. She is experienced in international investments, management and financial advisory. She has provided her expertise in the areas of the private sector finance, project development, environmental studies, economic studies, project planning and funding, policy writing/implementation and evaluation, feasibility studies, and financial consulting to several start-up companies worldwide.

18

Organizational Structure◦ The importance of having those skilled in the art as a

part of our team is well-known. An experienced V.P. of Sales and Marketing is currently being sought. The desired profile is for someone experienced in the medical marketing/distribution arena, ideally someone who was a part of a previous start-up venture that grew to exceed a minimum $20 million in sales. It is also imperative for us to add a clinical scientist to our staff as soon as funding will allow. Some of our tasks can also be handled by outside consultants in the early going. Additionally, the management team will also include an advisory board which is currently being assembled. The Board of Directors is currently open.

19

Marc G. Rioult, PhD, MBA, MS - Experience in business development and technology commercialization, including strategic planning, valuation, deal structuring, and negotiations. Skilled in competitive environment analysis, marketing, and sales channel management. Over ten years experience working as a consultant with organizations ranging from start-ups to Fortune 500 corporations in the U.S. and overseas. Fifteen years experience in academic research or with government or corporate research labs in the U.S. and in Europe. He was formerly a commercialization specialist at MIT.

Donald Rhodes, Area Director, The University of Georgia Small Business Development CenterB.A. in Economics, Mercer UniversityM.S.A. in Management, Georgia College and State UniversityED.S. in Educational Leadership, The University of Georgia Area Director in MaconMr. Rhodes has an extensive background in operations, customer service, and accounting. He acquired comprehensive experience in management and business operations with two heating and air conditioning contracting firms. Prior to joining the Small Business Development Center, he was employed by Barge Management Services as their service manager. His areas of interest include sales, service, and family-owned businesses.

20

Dean P. Remy, MT (ASCP, NCA) President & CEO SCiSOURCE, Inc. and LLC and Cofounder Nexur LLCA Life Sciences commercialization professional with 20+ years dedicated to this industry. Dean Remy has held numerous positions in Sales, Sales Management, Business Development, Marketing, and Product Management in both the Life Science and Clinical Diagnostics marketplace for 2 decades. He has worked with companies ranging from Start-Up conceptual to worldwide global leaders with hundreds of thousands of products to support.

John Maclennan, Ph.D., MBADr. Maclennan has had an extensive career in separations technologies and their application to the biological, pharmaceutical and diagnostic markets. He has 30 years of experience in separations companies such as Waters, where he had marketing and product management responsibility for the consumables product lines, as well as companies, such as Dyax where he was responsible for marketing and selling the company’s affinity chromatography business to companies manufacturing biopharmaceuticals. Subsequent to this, Dr. Maclennan has had a variety of sales roles into the drug discovery, development, biomanufacturing, and the clinical & molecular diagnostics segments.

21

Steven Munevar, Ph.D., M.B.A. President & CEO Munevar & Associates, Inc. Summary:

Focused on bridging innovations and discoveries from the research bench to patient bedside through technology development and commercialization by providing multidisciplinary experience and expertise in biomedical science, bio-engineering and business management

Background: Ph.D. - Biomedical scientist with an emphasis on cellular and

molecular physiology and cell biology M.B.A. - Business management with a focus on new venture

creation and commercialization B.S. - Bioengineer with emphasis on biomedical devices and

biomimetic materials

22

Winston Patrick Kuo, D.D.S., D.M.Sc.Director, Harvard Catalyst - LITT, Harvard Medical School Instructor, Department of Developmental Biology, Harvard School of Dental MedicineMunevar & Associates, Inc.

Dr. Kuo is currently a Biomedical Informatics Research Fellow in several labs throughout Harvard Medical School: Decision System’s Group at the Brigham and Women’s Hospital (www.dsg.harvard.edu), Children’s Hospital Informatics Program (www.chip.org), and the Department of Genetics (http://genetics.med.harvard.edu/~cepko/). His research is divided into technical and biological aspects in Genomics and Bioinformatics (Computational Biology). He is currently evaluating commercial and academic high-throughput technologies that measure gene expression profiles, in terms of their accuracy, comparability, sensitivity, specificity, and reproducibility that will benefit the biomedical research community as this technology becomes universally accepted.

23

Advanced Preservation Technologies, LLC. will issue an unsecured convertible note in increments of ____________________dollars to raise $300,000 in funding to further develop the product.

For an investment of $________________ , Advanced Preservation Technologies, LLC. will execute an unsecured convertible promissory note in your favor. The principal plus 10% interest will be payable when financing is obtained. You will have the option to convert the principal of $_______________________ into equity in Advanced Preservation Technologies, LLC. At the Company’s discretion, the Company may accept investments in the Notes in an aggregate amount of more or less than the initially anticipated amount of $300,000 unsecured which will be convert to Stock at a rate equivalent to the per share price at which shares of the Stock are sold in the Qualified Financing multiplied by 0.80 to compensate for the degree of risk associated with the start up. None of the above may be realized if financing is not secured. The funds will be at risks and investment is suitable only for persons with the financial capability to make and hold long-term investments not readily converted into cash. Investors must, therefore, have adequate means of providing for their current and future needs and personal contingencies. The funds will be used as described in the “Use of Proceeds for startup capital”.

24

Secure biopolymer and negotiate a sales and distribution agreement with supply house.

Modify, test and launch urine preservative

◦ Engage Dr. Gaul/Emory University to assist with achieving 6 days of preservation of urine.

◦ Immediately market product for 24hr voids

◦ Determine other applications for urine i.e. Bard bags

Test blood, plasma and serum applications and publish data.

◦ Determine best methods of commercialization and marketing

Schedule

Secure agreement on bio-ploymer. Launch

bioploymer.Complete modification of preservative 1Q13

Launch blood tubes and urine tubes

3Q13

Evaluate other uses for products3Q13

Test blood, plasma and serum. Outsource tubes,

get 510k approvals1Q13

25

We believe we have a dynamic product with huge potential. The beauty of our product is that:

No FDA approvals are required for research applications. Therefore product has immediate applications.

The In-Vitro Diagnostic market is enormous and we have acquired worldwide exclusive rights to product.

Captive audience of the two largest clinical laboratories in the country awaiting our product.

We also have the bio-polymer serving as a safety net for our investors.

26

27

Profound Technologies, Inc.

115 Mauldon Court

Warner Robins, Georgia 31093

mrfitz31@yahoo.com

(478) 923-2023 wk

(478) 320-2701 cell

(570) 227-2712 efax